ClinicalTrials.gg
CompletedNCT05415540MRKHPSYUpdated Nov 20, 2025

Evolution of the Quality of Life and Experience of Young Women With Utero-vaginal Aplasia (MRKHPSY)

An observational study in Mrkh Syndrome, sponsored by Assistance Publique - Hôpitaux de Paris. Completed at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-20.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
25
Ages
18 Years and older
Sex
Female
01

Study summary

This study aims to evaluate the global evolution of the quality of life on patients diagnosed with MRKH syndrome (Mayer-Rokitansky-Kuster-Hauser), 8 to 10 years after the first research.

Read the detailed description

Between 2012 and 2015, the French national reference center for rare gynecological pathologies (PGR) has conducted a study with 2 axis: a medical and a psychological section (clinical trial number NCT01911884).

The medical axis's aim was to compare the global and sexual quality of life of MRKH patients according to the mode of care (surgical or non-surgical) for vaginal aplasia. A total of 131 patients, with a mean age of 26.5 (±5.5) years old, were recruited for the study.

The quality of life was assessed considering 3 quality of life scales: global (WHOQOL-BREF) and sexual (FSFI and FSDS-R).

Quality of life scores and vaginal depth were compared and revealed that the surgery was not superior to self-dilation, whether in terms of quality of life or anatomical results. In addition, surgery was associated with complications in half of the cases. It should be mentioned that the overall quality of life of all 131 patients was similar to that of the general population, but significantly impaired in the psychosocial dimension in the younger patients. Notably, the quality of sexual life was not impaired with FSFI scores similar to those of the general population, but there was a profound sexual distress in nearly 71% of patients according to FSDS-R scores.

The psychological component of this initial research (called T1) focused specifically on the psychological, and more widely on the psychosocial, impact of the diagnosis of utero-vaginal aplasia in adolescent girls. 40 patients out of the 131 in the medical component participated (the first 40 contacted to participate in the medical component research). The results revealed a real experience of disability, and unexpectedly, addictive reactionary disorders (anorexia/bulimia or sport addiction), and an overrepresentation of heterosexual orientation compared to the general population. The absence of a uterus led to severe moral suffering regarding projections of access to biological motherhood.

This new research (called T2) involves the same population as T1 with the object of making each patient her own witness.

The purpose of the current study is to assess the evolution of this suffering, 8 to 10 years after the T1 study, using the same methodology as the previous study. The investigators hope to find an improvement in quality of life, a disappearance of addictive disorders and possibly a more vivid, but painful expression due to age, of the desire for motherhood, even if the uterus transplant is a source of hope.

Finding predictive factors of psychosocial difficulties would allow teh investigators to improve care practices, mainly psychological, which could also benefit other women with a rare disease affecting their sexuality and/or fertility.

02

Conditions studied

  • Mrkh Syndrome

Browse trials for

Keywords

  • Mayer-Rokitansky-Kuster-Hauser Syndrome
  • Quality of life
  • Utero-vaginal aplasia
03

In context

Mullerian aplasia

20 studies on the registry are indexed under Mullerian aplasia; 11 are open to participants now.

Browse Mullerian aplasia studies →

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,596 studies on the registry; 1,037 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patient who participated in the initial T1 psychological component of the previous study (MRKH protocol)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient aged of 18 years old or older
  • Patient who participated in the initial T1 psychological component of the previous study (MRKH protocol)

Exclusion criteria

Exclusion Criteria

- Refusal to participate in the study

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
25 participants (actual)
Patient registry
No

Interventions

  • OtherQuestionnaires

    Subjects included in the study will answer questionnaires

06

What researchers measure

Primary outcomes

  1. Evaluation of global quality of life

    Evaluated by the World Health Organization Quality Of Life Brief Version (WHOQOL-BREF)

    Time frame: Day 0

Secondary outcomes

  1. Socio-professional integration

    Socio-professional integration based on professional integration criteria. The potential consequences of this malformation on socio-professional integration are also diagnosed during the semi-directive clinical consultation and with the quality of life scale: \- Total score WHOQOL-BREF

    Time frame: Day 0

  2. Socio-professional integration

    Socio-professional integration based on professional integration criteria. The potential consequences of this malformation on socio-professional integration are also diagnosed during the semi-directive clinical consultation and with the quality of life scale: \- item 18 score (How satisfied are you with your capacity for work?)

    Time frame: Day 0

  3. Socio-professional integration

    Socio-professional integration based on professional integration criteria. The potential consequences of this malformation on socio-professional integration are also diagnosed during the semi-directive clinical consultation and with the quality of life scale: -qualitative components mentioned during the clinical consultation regarding education and socio-professional integration

    Time frame: Day 0

  4. Sexual quality of life

    Sexual quality of life is assessed by two sex life self-questionnaires (Female Sexual Function Index FSFI and Female Sexual Dysfunction Scale-Revised FSFD).

    Time frame: Day 0

  5. Addictive behavioural disorders

    Description : Addictive behavioural disorders are diagnosed during the semi-directive clinical consultation. The semi-directive clinical consultation aims to promote the production of a speech by the patient on a given theme. This will be about the evolution of the personal history when the diagnosis was announced and the medical and/or surgical consequences that this diagnosis induced.

    Time frame: Day 0

  6. Desire for motherhood

    The desire for motherhood is identified during the semi-directive clinical consultation.

    Time frame: Day 0

  7. The modalities to access to maternity

    The modalities to access to maternity is identified during the semi-directive clinical consultation with three items: adoption, surrogacy, uterus transplantation;

    Time frame: Day 0

  8. Modalities of their psychic functioning

    by the semi-directive clinical interview and the Rorschach\&TAT with 13 variables: * Adaptation to reality * Type of anxiety:castration, loss of object, fragmentation, intrusion * Body image and characteristics of human responses :whole, partial, blurred, attacked * Self-representation:solid/fragile * Capacity to deploy conflictual scenarios * Female identification capability * Access to ambivalence * Modalities of thought investment: quality of laboration of the modes of apprehension: good/inadequate * Quality of psychic functioning and defensive range: flexible and adapted/rigid and adapted/flexible and inadapted/rigid and inadapted

    Time frame: Day 0

07

Study locations

1 site
  • Necker Children's Hospital
    Paris, 75015, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2022 to primary completion in Feb 2024, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2022
First posted
Jun 13, 2022
StartActual
Oct 4, 2022
Primary completionActual
Feb 27, 2024
CompletionActual
Feb 27, 2024
Last update
Nov 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05415540
Collaborators
Foundation for Rare Diseases, Necker Imagine Foundation, Laboratory of Clinical Psychology, Psychopathology and Psychoanalysis, URC-CIC Paris Descartes Necker Cochin
Responsible party
Sponsor
First posted
Jun 13, 2022
Start date
Oct 4, 2022
Primary completion
Feb 27, 2024
Completion
Feb 27, 2024
Last update
Nov 20, 2025

Study contacts

Alaa CHEIKHELARD, Doctor
principal investigator
Karinne Gueniche, MD, PhD
study director

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion